| 卡马西平所致药疹与CYP3A4＊18B基因型的关联性初探 |
| |
| 引用本文： | 王倩,潘军利,周列民,方子妍,陈柳静,陈树达,陈子怡,杨丽白,蔡晓冬,周珏倩.卡马西平所致药疹与CYP3A4＊18B基因型的关联性初探[J].分子诊断与治疗杂志,2011,3(4):232-236. |
| |
| 作者姓名： | 王倩 潘军利 周列民 方子妍 陈柳静 陈树达 陈子怡 杨丽白 蔡晓冬 周珏倩 |
| |
| 作者单位： | 王倩,周列民,方子妍,陈柳静,陈树达,陈子怡,杨丽白,蔡晓冬,周珏倩,WANG Qian,ZHOU Liemin,FANG Ziyan,CHEN Linjing,CHEN Shuda,CHEN Ziyi,YANG Libai,CAI Xiaodong,ZHOU Jueqian(中山大学附属第一医院神经内科,广东,广州,510080);潘军利,PAN Junli(广东省中山市人民医院神经内科,广东,中山,528403) |
| |
| 基金项目： | 国家自然科学基金，广东省科技计划 |
| |
| 摘 要： | 目的初步探讨卡马西平所致药疹与CYP3A4＊18B基因型的关系,以寻找预测药疹的分子学手段。方法用PCR-RFLP法检测65例卡马西平所致药疹组患者（重型药疹患者11名,轻型药疹患者54名）、100例卡马西平耐受组患者及100例健康对照组患者的CYP3A4＊18B（intron10,G20338→A）基因多态性。结果卡马西平所致药疹组CYP3A4＊1/CYP3A4＊1（G/G）基因型30例,CYP3A4＊1/CYP3A4＊18B（G/A）基因型30例,CYP3A4＊18B/CYP3A4＊18B（A/A）基因型5例,等位基因A频率为30.8%;卡马西平耐受组G/G基因型51例,G/A基因型42例,A/A基因型7例,等位基因A频率为28%;健康对照组G/G基因型44例,G/A基因型49例,A/A基因型7例,等位基因A频率为31.5%。各组间基因型与等位基因频率差异均无统计学意义。结论由于病例数较少,目前尚没有发现卡马西平药疹与CYP3A4＊18B相关联。
|
| 关 键 词： | 卡马西平 药疹 CYP3A4＊18B 关联性 |
Association between CYP3A4*18B genotype and Carbamazepine-Induced Cutaneous Adverse Reactions |
| |
| WANG Qian,PAN Junli,ZHOU Liemin,FANG Ziyan,CHEN Linjing,CHEN Shuda,CHEN Ziyi,YANG Libai,CAI Xiaodong,ZHOU Jueqian.Association between CYP3A4*18B genotype and Carbamazepine-Induced Cutaneous Adverse Reactions[J].Journal of Molecular Diagnosis and Therapy,2011,3(4):232-236. |
| |
| Authors: | WANG Qian PAN Junli ZHOU Liemin FANG Ziyan CHEN Linjing CHEN Shuda CHEN Ziyi YANG Libai CAI Xiaodong ZHOU Jueqian |
| |
| Institution: | 1. Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China; 2. Department of Neurology, The People＇s Hospital of Zhongshan, Zhongshan, Guangdong 528403, China) |
| |
| Abstract: | Objective To explore the association between CYP3A4＊18B genotype and carbamazepineinduced cutaneous adverse reactions and find the molecular method for predicting carbamazepine-induced cutaneous adverse reactions. Methods CYP3A4＊18B（intron 10, G20338 → A） genetic polymorphisms were detected by a polymerase chain reaction restriction fragment length polymorphism（PCR-RFLP） method on 65 subjects who had carbamazepine-induced cutaneous adverse reactions, including 11 patients with Stevens-Johnson syndrome or Toxic epidermal necrolysis and 54 patients with maculopapular eruption, 100 carbamazepine-tolerant controls, and 100 normal individuals. Results In carbamazepine-induced cutaneous adverse reaction group, there were 30 subjects with CYP3A4＊1/CYP3A4＊1（G/G） genotype, 30 subjects with CYP3A4＊1/CYP3A4＊18B（G/A） genotype, and 5 subjects with CYP3A4＊18B/CYP3A4＊18B（A/A） genotype. The frequency of allele A was 30.8%. In carbamazepinetolerant controls, 51 subjects were G/G genotype, 42 subjects were G/A genotype, and 7 subjects were A/A genotype. The frequency of allele A was 28%. In normal individuals, 44 subjects were G/G genotype, 49 subjects were G/A genotype, and 7 subjects were A/A genotype. The frequency of allele A was 31.5%. The difference of neither the frequency of CYP3A4＊18B genotype nor the one of allele A between carbamazepine-induced cutaneous adverse reactions group and carbamazepine-tolerant controls had any statistical significance, and the same result was found between carbamazepine-induced cutaneous adverse reactions groups and normal controls. Conclusion The data could not show any association between carbamazepine-induced cutaneous adverse reactions and CYP3A4＊18B. |
| |
| Keywords: | CYP3A4*18B |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
